Optimal management of ALK-positive NSCLC progressing on crizotinib.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.02.003
Abstract: Crizotinib is an anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (-TKI) that represents the standard first-line treatment of patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer (NSCLC). In this setting, crizotinib has demonstrated a response… read more here.
Keywords: nsclc; alk; alk tki; crizotinib ... See more keywords
Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2133972
Abstract: Abstract Background The real-world treatment and outcomes of patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer treated with ALK Tyrosine Kinase Inhibitor (TKI) drugs in Sweden is not well described. Material… read more here.
Keywords: kinase; alk tki; clinical practice; alk ... See more keywords
Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
Sign Up to like & getrecommendations! Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13143
Abstract: Most non‐small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase‐tyrosine kinase inhibitor (ALK‐TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK‐TKI therapies; however, little… read more here.
Keywords: alk; alk tki; nsclc patients; short progression ... See more keywords
Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21122
Abstract: e21122Background: Ensartinib (X-396) is a novel, selective, oral ALK inhibitor with 10-fold higher potency than crizotinib, which is effective and well tolerated in US ALK+ NSCLC patients at 225 mg... read more here.
Keywords: alk; alk tki; ensartinib 396; second generation ... See more keywords
Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
Sign Up to like & getrecommendations! Published in 2018 at "OncoTargets and therapy"
DOI: 10.2147/ott.s165511
Abstract: The identification of anaplastic lymphoma kinase (ALK), an oncogenetic driver mutation, in lung cancer has paved the way for a new era in the treatment of non-small cell lung cancer (NSCLC). Targeting ALK using tyrosine… read more here.
Keywords: alk; alk tki; treatment; spotlight lorlatinib ... See more keywords